Etravirine–raltegravir, a marked interaction in HIV-1-infected patients: about four cases

• Published in: AIDS (London) Vol. 23; no. 7; pp. 869 - 871
• Main Authors: Ménard, Amélie, Solas, Caroline, Mokthari, Saadia, Bregigeon, Sylvie, Drogoul, Marie-Pierre, Tamalet, Catherine, Lacarelle, Bruno, Martin, Isabelle Poizot
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 27.04.2009
• Subjects: Anti-HIV Agents - administration & dosage; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiviral agents; Biological and medical sciences; Drug Interactions; HIV Infections - drug therapy; HIV Infections - immunology; HIV-1; Human immunodeficiency virus; Human viral diseases; Humans; Immunodeficiencies; Immunodeficiencies. Immunoglobulinopathies; Immunopathology; Infectious diseases; Medical sciences; Pharmacology. Drug treatments; Pyridazines - administration & dosage; Pyrrolidinones - administration & dosage; Raltegravir Potassium; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Viral Load; Immunopathology; Antiretroviral agent; RNA-directed DNA polymerase; Enzyme; Non nucleoside compound; Transferases; AIDS; Immune deficiency; Infection; Nucleotidyltransferases; Integrase inhibitor; Reverse transcriptase inhibitor; Viral disease; Etravirine; Antiviral; Raltegravir
• ISSN: 0269-9370; 1473-5571; 1473-5571
• DOI: 10.1097/QAD.0b013e328329915f

Recently, new compounds, capable of overcoming the extensive class resistances observed in multitreated patients, became available for HIV-infected patients. Raltegravir (RAL) is the first compound of a new class of antiretrovirals, the integrase inhibitors. Etravirine (ETV), a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), has been demonstrated to be active against HIV strains presenting resistance to first-generation NNRTI.